Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
124162003 | 12416200 | 3 | F | 201512 | 20160809 | 20160530 | 20160819 | EXP | PE-PFIZER INC-2016271836 | PFIZER | 77.00 | YR | F | Y | 0.00000 | 20160819 | CN | PE | PE |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
124162003 | 12416200 | 1 | PS | XALATAN | LATANOPROST | 1 | UNK, AT NIGHTS | U | M38075|M78311|M79117 | 20597 | EYE DROPS, SOLUTION | QD | |||||||
124162003 | 12416200 | 2 | SS | UNIAL | HYALURONATE SODIUM | 1 | UNK, EVERY 8 HOURS | U | 0 | TID | |||||||||
124162003 | 12416200 | 3 | SS | KRYTANTEK | BRIMONIDINE TARTRATEDORZOLAMIDE HYDROCHLORIDETIMOLOL MALEATE | 1 | UNK, 2X/DAY | U | 0 | BID |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
124162003 | 12416200 | 1 | Glaucoma |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
124162003 | 12416200 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
124162003 | 12416200 | Abasia | |
124162003 | 12416200 | Osteoarthritis | |
124162003 | 12416200 | Osteoporosis | |
124162003 | 12416200 | Rheumatoid arthritis | |
124162003 | 12416200 | Spinal disorder | |
124162003 | 12416200 | Urinary tract infection | |
124162003 | 12416200 | Visual impairment |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |